Get the Stockscreener App
24.11
1.99%
0.47
Pre-market:
24.55
0.44
+1.82%
Ideaya Biosciences Inc stock is traded at $24.11, with a volume of 556.60K.
It is up +1.99% in the last 24 hours and down -7.27% over the past month.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
See More
Previous Close:
$23.64
Open:
$23.61
24h Volume:
556.60K
Relative Volume:
0.66
Market Cap:
$2.08B
Revenue:
$23.38M
Net Income/Loss:
$-155.22M
P/E Ratio:
-11.01
EPS:
-2.19
Net Cash Flow:
$-134.36M
1W Performance:
+1.05%
1M Performance:
-7.27%
6M Performance:
-39.86%
1Y Performance:
-45.61%
1-Day Range:
$23.31
$24.31
1-Week Range:
$23.29
$24.97
52-Week Range:
$22.10
$47.73
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Name
Ideaya Biosciences Inc
Sector
Industry
Phone
650-443-6209
Address
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare IDYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
24.11 | 2.08B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
482.28 | 124.20B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.05 | 76.60B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
651.30 | 39.57B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.00 | 34.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.14 | 28.08B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Stephens | Overweight |
| Nov-05-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Mar-08-24 | Initiated | BTIG Research | Buy |
| Aug-08-23 | Initiated | SVB Securities | Outperform |
| May-24-23 | Initiated | Goldman | Buy |
| Apr-24-23 | Upgrade | Stifel | Hold → Buy |
| Mar-23-23 | Initiated | Berenberg | Buy |
| Feb-28-23 | Initiated | RBC Capital Mkts | Outperform |
| Dec-28-22 | Initiated | CapitalOne | Overweight |
| Oct-27-22 | Initiated | Citigroup | Buy |
| Aug-15-22 | Downgrade | Stifel | Buy → Hold |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Mar-10-22 | Upgrade | Stifel | Hold → Buy |
| Sep-23-21 | Initiated | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-11-21 | Initiated | Guggenheim | Buy |
| Oct-07-20 | Initiated | Wedbush | Outperform |
| Sep-01-20 | Initiated | Northland Capital | Outperform |
| Jul-13-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-17-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-06-20 | Initiated | H.C. Wainwright | Buy |
| Mar-13-20 | Initiated | ROTH Capital | Buy |
| Oct-17-19 | Initiated | Oppenheimer | Outperform |
| Sep-10-19 | Initiated | Robert W. Baird | Outperform |
| Jun-17-19 | Initiated | Citigroup | Buy |
| Jun-17-19 | Initiated | JP Morgan | Neutral |
| Jun-17-19 | Initiated | Jefferies | Buy |
View All
Ideaya Biosciences Inc Stock (IDYA) Latest News
Take off with Ideaya Biosciences Inc (IDYA): Get ready for trading - SETE News
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
SG Americas Securities LLC Boosts Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDYAIDEAYA Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
IDEAYA Awards Strategic Stock Options Package: Key Details for New Hires Revealed - StockTitan
12 Stocks That Will Double in 2025 - Insider Monkey
Uncover the Top 12 Stocks Set to Skyrocket by 2025! - Reporteros del Sur -
Here’s Why IDEAYA Biosciences, Inc. (IDYA) Will Double in 2025 - Insider Monkey
BTIG reiterates Buy on Ideaya stock, cites significant updates - MSN
Mizuho Initiates Coverage of IDEAYA Biosciences (IDYA) with Outperform Recommendation - MSN
IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events - Nasdaq
IDEAYA Biosciences to Present at Major Healthcare Investment Conferences - StockTitan
(IDYA) Technical Data - Stock Traders Daily
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation - Yahoo Finance
Cantor Fitzgerald Weighs in on IDYA FY2025 Earnings - Defense World
Brokers Issue Forecasts for IDYA FY2025 Earnings - MarketBeat
BTIG reiterates Buy on Ideaya stock, cites significant updates By Investing.com - Investing.com Canada
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
JPMorgan Chase & Co. Grows Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - MarketBeat
Ideaya stock touches 52-week low at $22.15 amid market challenges - MSN
Short Interest in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Expands By 10.1% - MarketBeat
IDEAYA Biosciences (IDYA): A Down Year Presents a Window of Opportunity for Investors - MSN
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 1-Year LowHere's Why - MarketBeat
IDEAYA Biosciences’ (IDYA) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Ideaya stock touches 52-week low at $22.15 amid market challenges By Investing.com - Investing.com South Africa
Leerink Partners Downgrades IDEAYA Biosciences (IDYA) - MSN
Learn to Evaluate (IDYA) using the Charts - Stock Traders Daily
Royal Bank of Canada Reaffirms "Outperform" Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
IDEAYA Biosciences (NASDAQ:IDYA) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
IDEAYA Biosciences (NASDAQ:IDYA) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance - Marketscreener.com
IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance – Company Announcement - Financial Times
IDEAYA Biosciences (NASDAQ:IDYA) Hits New 12-Month Low – Here’s Why - Defense World
Ideaya Biosciences stock hits 52-week low at $24.14 By Investing.com - Investing.com Australia
IDEAYA Biosciences (NASDAQ:IDYA) Reaches New 1-Year LowShould You Sell? - MarketBeat
Ideaya Biosciences stock hits 52-week low at $24.14 - Investing.com
Analysts Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Price Target at $53.67 - MarketBeat
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
IDEAYA Biosciences' SWOT analysis: oncology biotech stock's potential and risks - Investing.com Australia
IDEAYA Biosciences' SWOT analysis: oncology biotech stock's potential and risks By Investing.com - Investing.com South Africa
Principal Financial Group Inc. Sells 4,968 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences (NASDAQ:IDYA) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Another Major DLL3 ADC Alliance As Hengrui Links With IDEAYA - News & Insights
Pfizer exits Sangamo pact; Roche, Ideaya strike ADC deals - BioPharma Dive
IDEAYA Biosciences in-licenses Hengrui’s SHR-4849 - The Pharma Letter
Ideaya Biosciences Inc Stock (IDYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.02%
0.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):